Third Rock Ventures added Casma Therapeutics Inc. to its string of biopharma startups, loading the Cambridge, Mass.-based company with a $58.5 million series A to exploit autophagy for the design of drugs targeting lysosomal storage, muscle and inflammatory diseases along with neurodegeneration – for starters, at least.